FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164609975> ?p ?o ?g. }

• W3164609975 endingPage "100193" @default.
• W3164609975 startingPage "100193" @default.
• W3164609975 abstract "EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivity for afatinib. Nevertheless, limited data have reported the clinical efficacy of afatinib in patients with NSCLC harboring G724S mutation.We identified 52 patients with NSCLC with EGFR G724S from an inhouse database and comprehensively profiled their concurrent mutation statuses. Treatments and clinical outcomes were also collected.Of 52 G724S-positive patients, 39 harbored concomitant EGFR exon 19 deletion (19del), and all 37 of the 39 patients who had available clinical data were detected with a G724S mutation after receiving EGFR TKIs. A rare variant of 19del E746_S752delinsV co-occurred with G724S the most frequently (n = 29), whereas 7 of 10 patients with concomitant EGFR exon 20 mutation were TKI treatment naive. S768I was the most common mutation in exon 20 (n = 7). One patient harbored a concomitant EGFR exon 21 mutation, and two lacked co-occurring EGFR mutations. A total of 23 patients provided valid clinical outcome data, of whom eight were treated with afatinib after the emergence of G724S, whereas 15 received non-afatinib treatment (alternative EGFR TKI, chemotherapy, or best supportive care). The disease control rate in afatinib-treated patients (n = 8) reached 100% with a median progression-free survival of 4.5 months, significantly longer than that of non-afatinib-treated (n = 15, 1.7 mo, hazard ratio [HR] = 0.32, p = 0.037) and alternative EGFR TKI-treated (n = 11, 1.8 mo, HR = 0.28, p = 0.042) patients. In the subset who had progressed on osimertinib, afatinib also yielded a superior progression-free survival (6.2 mo) than non-afatinib therapies (1.0 mo, HR = 0.04, p = 0.005) and alternative EGFR TKIs (1.8 mo, HR = 0.06, p = 0.033). Analysis of acquired mutations at afatinib progression revealed re-emergence of EGFR T790M or MET amplification as the potential mechanism of afatinib resistance.EGFR G724S emerges as a resistant mutation against EGFR TKI preferentially in the context of a rare variant of 19del, whereas it might mediate differential mechanisms in the context of exon 20 mutation. We also found that afatinib could be a potential therapeutic option for patients with NSCLC with G724S." @default.
• W3164609975 created "2021-06-07" @default.
• W3164609975 creator A5003608372 @default.
• W3164609975 creator A5022526821 @default.
• W3164609975 creator A5022757746 @default.
• W3164609975 creator A5023899283 @default.
• W3164609975 creator A5042682579 @default.
• W3164609975 creator A5043928765 @default.
• W3164609975 creator A5046131158 @default.
• W3164609975 creator A5057346366 @default.
• W3164609975 creator A5083314011 @default.
• W3164609975 date "2021-07-01" @default.
• W3164609975 modified "2023-10-13" @default.
• W3164609975 title "Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S" @default.
• W3164609975 cites W1546552389 @default.
• W3164609975 cites W1984068087 @default.
• W3164609975 cites W1990013637 @default.
• W3164609975 cites W2062629045 @default.
• W3164609975 cites W2103441770 @default.
• W3164609975 cites W2106578986 @default.
• W3164609975 cites W2119180969 @default.
• W3164609975 cites W2133149289 @default.
• W3164609975 cites W2139804581 @default.
• W3164609975 cites W2155943701 @default.
• W3164609975 cites W2166084034 @default.
• W3164609975 cites W2507541911 @default.
• W3164609975 cites W2508624127 @default.
• W3164609975 cites W2594091947 @default.
• W3164609975 cites W2731518173 @default.
• W3164609975 cites W2770828094 @default.
• W3164609975 cites W2772771600 @default.
• W3164609975 cites W2790334227 @default.
• W3164609975 cites W2795708883 @default.
• W3164609975 cites W2894066036 @default.
• W3164609975 cites W2899325153 @default.
• W3164609975 cites W2903740294 @default.
• W3164609975 cites W2916137642 @default.
• W3164609975 cites W3007042140 @default.
• W3164609975 doi "https://doi.org/10.1016/j.jtocrr.2021.100193" @default.
• W3164609975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8474270" @default.
• W3164609975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34590038" @default.
• W3164609975 hasPublicationYear "2021" @default.
• W3164609975 type Work @default.
• W3164609975 sameAs 3164609975 @default.
• W3164609975 citedByCount "5" @default.
• W3164609975 countsByYear W31646099752022 @default.
• W3164609975 countsByYear W31646099752023 @default.
• W3164609975 crossrefType "journal-article" @default.
• W3164609975 hasAuthorship W3164609975A5003608372 @default.
• W3164609975 hasAuthorship W3164609975A5022526821 @default.
• W3164609975 hasAuthorship W3164609975A5022757746 @default.
• W3164609975 hasAuthorship W3164609975A5023899283 @default.
• W3164609975 hasAuthorship W3164609975A5042682579 @default.
• W3164609975 hasAuthorship W3164609975A5043928765 @default.
• W3164609975 hasAuthorship W3164609975A5046131158 @default.
• W3164609975 hasAuthorship W3164609975A5057346366 @default.
• W3164609975 hasAuthorship W3164609975A5083314011 @default.
• W3164609975 hasBestOaLocation W31646099751 @default.
• W3164609975 hasConcept C121608353 @default.
• W3164609975 hasConcept C126322002 @default.
• W3164609975 hasConcept C143998085 @default.
• W3164609975 hasConcept C170493617 @default.
• W3164609975 hasConcept C207103383 @default.
• W3164609975 hasConcept C2778820342 @default.
• W3164609975 hasConcept C2779384505 @default.
• W3164609975 hasConcept C2779438470 @default.
• W3164609975 hasConcept C2780580887 @default.
• W3164609975 hasConcept C2780586478 @default.
• W3164609975 hasConcept C42362537 @default.
• W3164609975 hasConcept C44249647 @default.
• W3164609975 hasConcept C71924100 @default.
• W3164609975 hasConceptScore W3164609975C121608353 @default.
• W3164609975 hasConceptScore W3164609975C126322002 @default.
• W3164609975 hasConceptScore W3164609975C143998085 @default.
• W3164609975 hasConceptScore W3164609975C170493617 @default.
• W3164609975 hasConceptScore W3164609975C207103383 @default.
• W3164609975 hasConceptScore W3164609975C2778820342 @default.
• W3164609975 hasConceptScore W3164609975C2779384505 @default.
• W3164609975 hasConceptScore W3164609975C2779438470 @default.
• W3164609975 hasConceptScore W3164609975C2780580887 @default.
• W3164609975 hasConceptScore W3164609975C2780586478 @default.
• W3164609975 hasConceptScore W3164609975C42362537 @default.
• W3164609975 hasConceptScore W3164609975C44249647 @default.
• W3164609975 hasConceptScore W3164609975C71924100 @default.
• W3164609975 hasIssue "7" @default.
• W3164609975 hasLocation W31646099751 @default.
• W3164609975 hasLocation W31646099752 @default.
• W3164609975 hasLocation W31646099753 @default.
• W3164609975 hasLocation W31646099754 @default.
• W3164609975 hasOpenAccess W3164609975 @default.
• W3164609975 hasPrimaryLocation W31646099751 @default.
• W3164609975 hasRelatedWork W1973291625 @default.
• W3164609975 hasRelatedWork W1992553266 @default.
• W3164609975 hasRelatedWork W2164207083 @default.
• W3164609975 hasRelatedWork W2807828246 @default.
• W3164609975 hasRelatedWork W2962865776 @default.
• W3164609975 hasRelatedWork W2970336640 @default.
• W3164609975 hasRelatedWork W3169006468 @default.

• next